(CABA) Cabaletta Bio - Ratings and Ratios
T-Cell,Autoimmune,Pipeline,Biologic
CABA EPS (Earnings per Share)
CABA Revenue
Description: CABA Cabaletta Bio
Cabaletta Bio Inc (NASDAQ:CABA) is a biotechnology company listed on the NASDAQ exchange, operating in the biotechnology sub-industry. The companys stock is characterized by high volatility, as evidenced by its beta of 2.736, indicating that its stock price tends to be highly sensitive to market fluctuations.
From a financial perspective, Cabaletta Bio has a market capitalization of $124.39 million, with a negative Return on Equity (RoE) of -92.11%, suggesting significant losses. The absence of a Price-to-Earnings (P/E) ratio, either current or forward, further indicates that the company is not generating profits. Key economic drivers for the company would likely include the success of its pipeline products, particularly in the biotechnology space where R&D expenditure is a critical factor.
To evaluate the companys performance, relevant KPIs could include R&D spend as a percentage of revenue, cash burn rate, and the progression of its clinical trials. The companys ability to secure funding, either through equity, debt, or partnerships, will be crucial in sustaining its operations and advancing its product pipeline. The stocks technical indicators, such as its Relative Strength Index (RSI) and Moving Averages, could provide insights into its short-term price movements and potential trading opportunities.
Investors should closely monitor the companys cash position, as significant cash burn is common in the biotechnology sector due to high R&D costs. The companys valuation and potential for future profitability will depend on the successful development and commercialization of its products. Given the high-risk nature of biotechnology investments, a thorough analysis of Cabaletta Bios financials, product pipeline, and competitive landscape is essential for making informed investment decisions.
CABA Stock Overview
| Market Cap in USD | 144m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-10-25 |
CABA Stock Ratings
| Growth Rating | -8.87% |
| Fundamental | 27.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -57.5% |
| Analyst Rating | 4.50 of 5 |
CABA Dividends
Currently no dividends paidCABA Growth Ratios
| Growth Correlation 3m | -12.1% |
| Growth Correlation 12m | -79.4% |
| Growth Correlation 5y | -24.3% |
| CAGR 5y | 39.81% |
| CAGR/Max DD 3y | 0.42 |
| CAGR/Mean DD 3y | 1.08 |
| Sharpe Ratio 12m | -1.43 |
| Alpha | 0.01 |
| Beta | 0.983 |
| Volatility | 98.81% |
| Current Volume | 2563.7k |
| Average Volume 20d | 1230.1k |
| Stop Loss | 1.8 (-9.5%) |
| Signal | 1.22 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-144.3m TTM) > 0 and > 6% of Revenue (6% = 98.3k TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -15.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9577 % (prev 4697 %; Δ 4880 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.47 (>3.0%) and CFO -104.7m > Net Income -144.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (61.9m) change vs 12m ago 25.14% (target <= -2.0% for YES) |
| Gross Margin -34.07% (prev 62.34%; Δ -96.41pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.74% (prev 1.84%; Δ -1.10pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -86.16 (EBITDA TTM -137.1m / Interest Expense TTM 1.61m) >= 6 (WARN >= 3) |
Altman Z'' -15.70
| (A) 0.70 = (Total Current Assets 198.4m - Total Current Liabilities 41.5m) / Total Assets 224.5m |
| (B) -1.92 = Retained Earnings (Balance) -430.2m / Total Assets 224.5m |
| warn (B) unusual magnitude: -1.92 — check mapping/units |
| (C) -0.63 = EBIT TTM -139.0m / Avg Total Assets 221.0m |
| (D) -9.35 = Book Value of Equity -430.2m / Total Liabilities 46.0m |
| Total Rating: -15.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.18
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.18 = -2.50 |
| 6. ROIC - WACC (= -97.20)% = -12.50 |
| 7. RoE -92.11% = -2.50 |
| 8. Rev. Trend 12.61% = 0.95 |
| 9. EPS Trend -85.17% = -4.26 |
What is the price of CABA shares?
Over the past week, the price has changed by +21.34%, over one month by +12.43%, over three months by +2.84% and over the past year by -49.49%.
Is Cabaletta Bio a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CABA is around 1.51 USD . This means that CABA is currently overvalued and has a potential downside of -24.12%.
Is CABA a buy, sell or hold?
- Strong Buy: 8
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CABA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.6 | 480.9% |
| Analysts Target Price | 11.6 | 480.9% |
| ValueRay Target Price | 1.7 | -15.6% |
Last update: 2025-09-05 04:36
CABA Fundamental Data Overview
CCE Cash And Equivalents = 194.7m USD (Cash And Short Term Investments, last quarter)
P/B = 0.802
Beta = 2.736
Revenue TTM = 1.64m USD
EBIT TTM = -139.0m USD
EBITDA TTM = -137.1m USD
Long Term Debt = 4.48m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 20.4m USD (from shortTermDebt, last quarter)
Debt = 24.9m USD (Calculated: Short Term 20.4m + Long Term 4.48m)
Net Debt = -120.7m USD (from netDebt column, last quarter)
Enterprise Value = -26.2m USD (143.6m + Debt 24.9m - CCE 194.7m)
Interest Coverage Ratio = -86.16 (Ebit TTM -139.0m / Interest Expense TTM 1.61m)
FCF Yield = -345.3% (FCF TTM -90.4m / Enterprise Value -26.2m)
FCF Margin = -5521 % (FCF TTM -90.4m / Revenue TTM 1.64m)
Net Margin = -8809 % (Net Income TTM -144.3m / Revenue TTM 1.64m)
Gross Margin = -34.07% ((Revenue TTM 1.64m - Cost of Revenue TTM 2.20m) / Revenue TTM)
Tobins Q-Ratio = 0.06 (Enterprise Value -26.2m / Book Value Of Equity -430.2m)
Interest Expense / Debt = 2.29% (Interest Expense 571.0k / Debt 24.9m)
Taxrate = 21.0% (US default)
NOPAT = -139.0m (EBIT -139.0m, no tax applied on loss)
Current Ratio = 4.78 (Total Current Assets 198.4m / Total Current Liabilities 41.5m)
Debt / Equity = 0.14 (Debt 24.9m / last Quarter total Stockholder Equity 178.5m)
Debt / EBITDA = -0.18 (Net Debt -120.7m / EBITDA -137.1m)
Debt / FCF = -0.28 (Debt 24.9m / FCF TTM -90.4m)
Total Stockholder Equity = 156.7m (last 4 quarters mean)
RoA = -64.27% (Net Income -144.3m, Total Assets 224.5m )
RoE = -92.11% (Net Income TTM -144.3m / Total Stockholder Equity 156.7m)
RoCE = -86.26% (Ebit -139.0m / (Equity 156.7m + L.T.Debt 4.48m))
RoIC = -88.72% (NOPAT -139.0m / Invested Capital 156.7m)
WACC = 8.48% (E(143.6m)/V(168.5m) * Re(9.64%)) + (D(24.9m)/V(168.5m) * Rd(2.29%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.19 | Cagr: 7.13%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -90.4m)
EPS Correlation: -85.17 | EPS CAGR: -52.17% | SUE: -1.89 | # QB: 0
Revenue Correlation: 12.61 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for CABA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle